Action OUTLOOK THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues OUTLOOK THERAPEUTICS, INC. Nasdaq

Actions

US69012T1079

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Corporate Presentation: June 2024
Outlook Therapeutics Receives European Commission Marketing Authorization for LYTENAVA for the Treatment of Wet AMD
Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD
CoStar Group has room for expansion
Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application for ONS-5010 as a Treatment for Wet AMD
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast
Outlook Therapeutics® to Present at the Retina World Congress 2024
Outlook Therapeutics, Inc. Announces Change in Headquarters Address
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC
Corporate Presentation: March 2024
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action OTLK
  4. Action
  5. Actualités OUTLOOK THERAPEUTICS, INC.
  6. Autres langues